Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators

Mona Malekzadeh Moghani; Zahra Siavashpour; Oleksander Ogorodniitchouk; Pablo Moreno-Acosta; Delphine Plattard; Alexis Vallard; Sandrine Sotton; Wafa Bouleftour; Julien Langrand-Escure; Nicolas Magné

doi:10.5114/jcb.2022.115330

eISSN: 2081-2841
ISSN: 1689-832X

Journal of Contemporary Brachytherapy

Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links

Editorial System

Submit your Manuscript

2/2022
vol. 14

Send email

Copy url:

abstract:

Original paper

Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators

Mona Malekzadeh Moghani

^{1, 2}

,

Zahra Siavashpour

¹

,

Oleksander Ogorodniitchouk

²

,

Pablo Moreno-Acosta

³

,

Delphine Plattard

²

,

Alexis Vallard

²

,

Sandrine Sotton

²

,

Wafa Bouleftour

²

,

Julien Langrand-Escure

²

,

Nicolas Magné

²

Department of Radiation-Oncology, Shohadaye Tajrish Educational Hospital, Shahid Beheshti University of Medical Sciences, Teheran, Iran
Department of Radiotherapy, Lucien Neuwirth Cancer Institute, Saint-Etienne, France
Research group in Cancer Biology, Research Branch, National Cancer Institute, Bogota, Colombia

J Contemp Brachytherapy 2022; 14, 2: 183–188

DOI: https://doi.org/10.5114/jcb.2022.115330

Online publish date: 2022/04/06

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Malekzadeh Moghani M, Siavashpour Z, Ogorodniitchouk O, et al. Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators. Journal of Contemporary Brachytherapy. 2022;14(2):183-188. doi:10.5114/jcb.2022.115330.

APA

Malekzadeh Moghani, M., Siavashpour, Z., Ogorodniitchouk, O., Moreno-Acosta, P., Plattard, D.,  & Vallard, A. et al. (2022). Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators. Journal of Contemporary Brachytherapy, 14(2), 183-188. https://doi.org/10.5114/jcb.2022.115330

Chicago

Malekzadeh Moghani, Mona, Zahra Siavashpour, Oleksander Ogorodniitchouk, Pablo Moreno-Acosta, Delphine Plattard, Alexis Vallard,  and Sandrine Sotton et al. 2022. "Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators". Journal of Contemporary Brachytherapy 14 (2): 183-188. doi:10.5114/jcb.2022.115330.

Harvard

Malekzadeh Moghani, M., Siavashpour, Z., Ogorodniitchouk, O., Moreno-Acosta, P., Plattard, D., Vallard, A., Sotton, S., Bouleftour, W., Langrand-Escure, J.,  and Magné, N. (2022). Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators. Journal of Contemporary Brachytherapy, 14(2), pp.183-188. https://doi.org/10.5114/jcb.2022.115330

MLA

Malekzadeh Moghani, Mona et al. "Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators." Journal of Contemporary Brachytherapy, vol. 14, no. 2, 2022, pp. 183-188. doi:10.5114/jcb.2022.115330.

Vancouver

Malekzadeh Moghani M, Siavashpour Z, Ogorodniitchouk O, Moreno-Acosta P, Plattard D, Vallard A et al. Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators. Journal of Contemporary Brachytherapy. 2022;14(2):183-188. doi:10.5114/jcb.2022.115330.

Purpose
The present study aimed to assess the correlation between dose to pelvic lymph nodes and to point B with tandem-ring (TR) applicators for intra-cavitary brachytherapy treatment of locally advanced cervical cancer.

Material and methods
Cervical cancer patients treated at brachytherapy department of Lucien Neuwirth Cancer Center, from 2015 to 2018, were included. Target delineation was performed in compliance with GEC-ESTRO guidelines. Revised American Brachytherapy Society (ABS) point A was determined (ARN (right) and ALN (left)) as well as Manchester point B. Prescription dose was 25-35 Gy in 5 fractions. Pelvic lymph nodes were delineated, then dose to points A and B, and dose-volume histogram (DVH) parameters of delineated lymph nodes were extracted. Significant relationships or correlations between lymph nodes reference points, dosage to points B, and their DVH parameters were investigated.

Results
The mean dose and mean percentage of the prescription dose to the left and right points B were 4.6 ±0.18 Gy and 82.08 ±0.72%, respectively. Pearson correlation coefficient R = 0.81 (p-value = 0.00) between dose to ARN and ALN points and prescription dose was obtained. Negative correlation between CTVHR volume and difference between French and ABS prescription points was found.

Conclusions
Dose to point B can be a moderate surrogate for maximum, minimum, and median dose to the internal iliac and presacral lymph node, but cannot be for maximum dose to the obturator lymph node. Points B cannot be a reliable substitute for common and external iliac chains.

keywords:

Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators

Mona Malekzadeh Moghani 1, 2 , Zahra Siavashpour 1 , Oleksander Ogorodniitchouk 2 , Pablo Moreno-Acosta 3 , Delphine Plattard 2 , Alexis Vallard 2 , Sandrine Sotton 2 , Wafa Bouleftour 2 , Julien Langrand-Escure 2 , Nicolas Magné 2

brachytherapy, cervical cancer, pelvic lymph node, tandem-ring applicator, point B

Mona Malekzadeh Moghani

^{1, 2}

,

Zahra Siavashpour

¹

,

Oleksander Ogorodniitchouk

²

,

Pablo Moreno-Acosta

³

,

Delphine Plattard

²

,

Alexis Vallard

²

,

Sandrine Sotton

²

,

Wafa Bouleftour

²

,

Julien Langrand-Escure

²

,

Nicolas Magné

²